Evidence map›Paper›PMID 42357309›Full record

ReviewPharmaceutics2026

Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.

Exequiel O J Porta, Dana F AlKharboush, Lauren Jackson, Felix Pang, Aylin Darin, Joy Louka, Mohammed Quamruzzaman, Xinyue Shi, Geoffrey Wells, Frank Kozielski

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Exequiel O J PortaUCL School of Pharmacy, University College London, London WC1N 1AX, UK.ORCID 0000-0002-7463-1468
Dana F AlKharboushUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Lauren JacksonUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Felix PangUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Aylin DarinUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Joy LoukaUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Mohammed QuamruzzamanUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Xinyue ShiUCL School of Pharmacy, University College London, London WC1N 1AX, UK.ORCID 0000-0003-0145-8761
Geoffrey WellsUCL School of Pharmacy, University College London, London WC1N 1AX, UK.
Frank KozielskiUCL School of Pharmacy, University College London, London WC1N 1AX, UK.ORCID 0000-0001-6096-9102

Funding

Medical Research Council MR/X013995/1
6 · The paper itself

Abstract

The SARS-CoV-2 non-structural proteome remains the most clinically validated and strategically important landscape for direct-acting small-molecule antiviral drug discovery. The success of inhibitors targeting the main protease (M

Indexed as

3C-like protease (3CLpro/Mpro)antiviral resistancedirect-acting antiviralsmain proteasenon-structural protein (Nsp)Nsp14/Nsp16 RNA capping enzymespan-coronavirus preparednesspapain-like protease (PLpro)RNA-dependent RNA polymerase (RdRp)SARS-CoV-2

Identifiers

PMID42357309
PMCPMC13305055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.